Pharmacology journal volume-13-issue 2
Journal link: https://pharmacologyjournal.org/
Submission 18 Jan 2025
Acceptance 9 Feb 2025
Publication 05 March 2025

Pathophysiological Mechanisms and Management Strategies in Age-Related Macular Degeneration

[1]Kamran Safdar, [2]Haroon Raja, [3]Tabssum Raja, [4]Dr Tanveer Ahmed, [5]Mohammad Younas Khan, [6]Hub e Ali

[1]Sir Gangaram Hospital Lahore.
[2]Mayo Hospital Lahore
[3]PIMS, Islamabad
[4]Assistant professor Eye CMH Kharian Medical College, Kharian Cantt
[5]Associate Professor Ophthalmology, Islamic International Medical College Trust / Riphah, International Hospital, Islamabad
[6]Services Hospital Lahore

Abstract

Background: Age-related macular degeneration (AMD) is one of the major causes of irreversible visual loss in the elderly, with a predilection for the macula and central vision.

Objective: The present article discusses the pathophysiological underpinnings of AMD, presents current treatment modalities, and presents results of ongoing management programs.

Methods: Clinical studies, epidemiology, and randomized clinical trials were examined to establish disease mechanisms and efficacy of treatments.

Results: Oxidative stress, inherited susceptibility, and retinal pigment epithelium (RPE) disease form the basis of AMD pathology. Anti-vascular endothelial growth factor (anti-VEGF) therapy significantly improves visual results in neovascular AMD, while antioxidant supplementation is of little value in dry AMD.

Conclusion:
AMD continues to be an important public health issue. While anti-VEGF therapies have transformed wet AMD management, preventive measures and novel therapies are essential for optimal treatment of the dry form.

Keywords:

Age-related macular degeneration, Retina, Anti-VEGF, Oxidative stress, Vision loss **Introduction**

AMD is a progressive, chronic retinal disorder that occurs mainly in people over the age of 55 years and is the most frequent cause of central vision loss in developed nations [1]. With the ageing population globally, AMD is on the rise and becoming an enormous socioeconomic as well as healthcare challenge [2]. The disease specifically attacks the macula, the central part of the retina that provides keen, clear vision used when reading, face recognition, and driving [3]. AMD may be of two types: dry (nonexudative) and wet

Pharmacology journal volume-13-issue 2
Journal link: https://pharmacologyjournal.org/
Submission 18 Jan 2025
Acceptance 9 Feb 2025
Publication 05 March 2025

Pharmacology journal volume-13-issue 2
Journal link: https://pharmacologyjournal.org/
Submission 18 Jan 2025
Acceptance 9 Feb 2025
Publication 05 March 2025

(exudative). The dry type, which is responsible for 85–90% of the cases, involves druse deposits, retinal pigment epithelium atrophy (RPE), and progressive degeneration of the photoreceptors [4]. In contrast, the wet type results from choroidal neovascularization through the action of vascular endothelial growth factor (VEGF), causing leakage, hemorrhage, and central vision loss [5].



While less frequent, wet AMD causes the most severe loss of sight seen with the condition. Pathophysiology of AMD is multifactorial and includes oxidative stress, chronic inflammation, genetic risk factors, and environmental factors like smoking and dietary indiscretion [6]. Oxidative damage to Bruch's membrane and RPE causing waste material deposition and defective photoreceptor support and thus propagation of the disease [7]. Genetic mutations of complement factor H and other genes in the complement pathway also contribute high susceptibility. AMD treatment has improved significantly in recent decades. In wet AMD, intra-vitreal anti-VEGF therapy has transformed outcomes with stabilization or even improvement in vision in most patients [8]. In dry AMD, treatment is not a certainty, but nutritional supplementation with antioxidants and zinc, as shown in the Age-Related Eye Disease Study (AREDS), was found to slow the progression of intermediate cases.

Pharmacology journal volume-13-issue 2
Journal link: https://pharmacologyjournal.org/
Submission 18 Jan 2025
Acceptance 9 Feb 2025
Publication 05 March 2025

Pharmacology journal volume-13-issue 2
Journal link: https://pharmacologyjournal.org/
Submission 18 Jan 2025
Acceptance 9 Feb 2025
Publication 05 March 2025



New treatments, including complement inhibitors, stem cell treatment, and gene treatment, are on the horizon to treat unmet needs, particularly dry AMD [9]. Even with all of these advances, AMD continues to be a leading cause of disability, where it remains necessary to have earlier diagnosis, risk factor modification, and personalized treatment protocols [10]. For this article, the pathophysiology of AMD is studied and existing management protocols assessed in order to fully appreciate this severe ocular disease.

Methodology

This study was performed by systematically searching the literature published between 2010 and 2024 through databases like PubMed, Cochrane Library, and clinical trial registries. Randomized controlled trials (RCTs), meta-analyses, and observational studies in the area of AMD pathophysiology and management were included. Keywords for the search were "age-related macular degeneration," "pathophysiology," "anti-VEGF," "oxidative stress," and "management." Inclusion were studies that assessed disease mechanisms, genetic correlates, or treatment intervention with at least six months of follow-up. Wet and dry AMD were both included. Exclusion were case reports, pediatric macular degeneration studies, and non-peer-studied articles. Data extraction was on risk factors, pathophysiological mechanisms, efficacy of anti-VEGF drugs, and outcomes of nutritional and preventive trials. Aggregated results and tabulated qualitatively to contrast treatment effects and complications.

Results

Evidence supports central mechanisms of oxidative stress, complement dysregulation, and genetic susceptibility in AMD. Anti-VEGF therapy was very effective in causing visual gain in wet AMD, whereas nutritional supplementation arrested progression in dry AMD but reversed no loss of vision.

Table 1: Pathophysiologic Factors in Age-Related Macular Degeneration (AMD)

Pharmacology journal volume-13-issue 2
Journal link: https://pharmacologyjournal.org/
Submission 18 Jan 2025
Acceptance 9 Feb 2025
Publication 05 March 2025

Pharmacology journal volume-13-issue 2
Journal link: https://pharmacologyjournal.org/
Submission 18 Jan 2025
Acceptance 9 Feb 2025
Publication 05 March 2025

Factor	Role in AMD Pathogenesis	Evidence Strength
Oxidative stress	Damages photoreceptors and RPE	Strong
Genetic mutations (CFH, ARMS2)	Increases susceptibility	Strong
Complement activation	Promotes inflammation	Moderate
Smoking	Enhances oxidative damage	Strong
Nutrition deficiency	Accelerates progression	Moderate

Table 2: Management Strategies and Outcomes

Intervention	Indication	Visual Outcome	Limitations

Pharmacology journal volume-13-issue 2
Journal link: https://pharmacologyjournal.org/
Submission 18 Jan 2025
Acceptance 9 Feb 2025
Publication 05 March 2025

Pharmacology journal volume-13-issue 2
Journal link: https://pharmacologyjournal.org/
Submission 18 Jan 2025
Acceptance 9 Feb 2025
Publication 05 March 2025

Anti-VEGF (ranibizumab, aflibercept)	Wet AMD	Stabilization/improvement of vision in 70–80%	Requires repeated injections
Photodynamic therapy	Wet AMD (select cases)	Limited improvement	Rarely firstline now
AREDS supplements	Intermediate/advanced dry AMD	Slows progression of AMD	No vision restoration
Complement inhibitors (experimental)	Dry AMD	Trial-suggestive promise	Not yet widely available

Discussion

This study highlights that age-related macular degeneration is a multifactorial disease with an etiology driven by a mix of genetic, environmental, and cellular factors [11]. Oxidative damage and RPE dysfunction remain pivotal in disease progression with compelling evidence indicating a causal role in accelerating risk by smoking, unhealthy diets, and genetic predisposition [12]. Deposition of druse and resultant complement activation fuel a cycle of retinal injury and inflammation resulting in ultimate irreversible photoreceptor loss. Treatment approaches are very dissimilar between dry and wet AMD. AntiVEGF therapy has revolutionized the prognosis for wet AMD, converting a disease formerly inextricably linked with blindness into a treatable disease [13]. Ranibizumab and aflibercept are just two of the medications that have been extremely successful, with stable or better vision in as many as 80% of

Pharmacology journal volume-13-issue 2
Journal link: https://pharmacologyjournal.org/
Submission 18 Jan 2025
Acceptance 9 Feb 2025
Publication 05 March 2025

patients. But the need for frequent intravitreal injections, cost of therapy, and compliance of the patient continue to be key issues, especially in resource-constrained environments [14]. Investigations on extended-release delivery systems and gene therapies are aimed at lessening the therapeutic burden. The future for dry AMD is less assured. AREDS-based therapy is of limited value, and the only consistent benefit is slowing the progression from intermediate to advanced disease. No treatment today, however, will regain lost vision [15]. The new developments with complement inhibitors, stem cell transplant, and neuro-protectants are promising but are still in the experimental phase. Public health interventions are also valuable. Early detection through conducting periodic ophthalmic screening, especially in the risk groups, can be beneficial for early intervention [16]. Patient education for the smoking behavior to be stopped, dietary modifications, and compliance with treatment guidelines is essential in decreasing disease burden. The results also justify the requirement of personalized treatment. Genetic testing, while not yet common practice, could one day inform risk stratification and management plans [17]. Moreover, ophthalmologists, genetic counselors, and rehabilitation specialists working together in a multidisciplinary approach can optimize patients' outcomes. In total, although much has been accomplished in the treatment of wet AMD, that of dry AMD remains a large medical need [18]. Ongoing research into molecular targets, regenerative medicine, and prevention will be essential in filling the gap and lessening the global impact of AMD.

Conclusion

Age-related macular degeneration is still a leading cause of visual disability, particularly among older populations. Recognition of its multifactorial etiology has dictated the course of successful treatments, notably of wet AMD using anti-VEGF therapy. Treatment of dry AMD at best is still restricted to prevention and nutritional supplements. Gene therapy, complement inhibition, and regenerative medicine are the solutions to more complete treatment in the future. Combined with individualized treatment, early diagnosis, and lifestyle modification, this approach is the most significant to confer the patient with the best possible outcome. **References**

1. Singh, M., Negi, R., Alka, Vinayagam, R., Kang, S. G., & Shukla, P. (2024). Age-related macular degeneration (AMD): pathophysiology, drug targeting approaches, and recent developments in nanotherapeutics. *Medicina*, *60*(10), 1647.
2. Boopathiraj, N., Wagner, I. V., Dorairaj, S. K., Miller, D. D., & Stewart, M. W. (2024). Recent updates on the diagnosis and management of age-related macular degeneration. *Mayo Clinic Proceedings: Innovations, Quality & Outcomes*, *8*(4), 364-374.
3. Quah, N. Q., Javed, K. M. A. A., Arbi, L., & Hanumunthadu, D. (2024). Real-world outcomes of faricimab treatment for neovascular age-related macular degeneration and diabetic macular edema. *Clinical Ophthalmology*, 1479-1490.
4. Khan, H., Aziz, A. A., Khanani, Z., Khan, H., Mojumder, O., Gahn, G. M., & Khanani, A. M. (2024). Approved treatments for neovascular age-related macular degeneration: current safety and future directions. *Expert Opinion on Drug Safety*, *23*(9), 1109-1114.

5. Zhang, C., AbouKasm, G., Lai, D. A., Leung, N., Zhu, D., Albini, T. A., & Yannuzzi, N. A. (2025). Clinical Efficacy of Switching to Faricimab in Treatment Resistant Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-analysis. *American journal of ophthalmology*.
6. Zur, D., Guymer, R., Korobelnik, J. F., Wu, L., Viola, F., Eter, N., ... & Arnold, J. J. (2025). Impact of residual retinal fluid on treatment outcomes in neovascular age-related macular degeneration. *British Journal of Ophthalmology*, *109*(3), 307-315.
7. Sim, S. Y., Chalkiadaki, E., Koutsocheras, G., Nicholson, L., Sivaprasad, S., Patel, P. J., ... & Saihan, Z. (2025). Real-world 1-year outcomes of treatment-intensive neovascular age-related macular degeneration switched to faricimab. *Ophthalmology Retina*, *9*(1), 22-30.
8. Raimondi, R., Falfeli, T., Bogdanova-Bennet, A., Varma, D., Habib, M., Kotagiri, A., ... & Grinton, M. (2024). Outcomes of treatment-resistant neovascular age-related macular degeneration switched from aflibercept to faricimab. *Ophthalmology Retina*, *8*(6), 537-544.
9. Wykoff, C. C., Garmo, V., Tabano, D., Menezes, A., Kim, E., Fevrier, H. B., ... & Leng, T. (2024). Impact of Anti-VEGF treatment and patient characteristics on vision outcomes in neovascular age-related macular degeneration: Up to 6-year analysis of the AAO IRIS® Registry. *Ophthalmology science*, *4*(2), 100421.
10. Qu, S., Lin, H., Pfeiffer, N., & Grus, F. H. (2024). Age-related macular degeneration and mitochondriaassociated autoantibodies: a review of the specific pathogenesis and therapeutic strategies. *International Journal of Molecular Sciences*, *25*(3), 1624.
11. Thomsen, A. K., Fasih-Ahmad, S., Sadda, S., & Sørensen, T. L. (2025). Initial treatment response can predict one-year treatment outcomes in neovascular age-related macular degeneration treated according to the observe-and-plan regimen. *Acta Ophthalmologica*, *103*(3), 304-312.
12. Brito, M., Sorbier, C., Mignet, N., Boudy, V., Borchard, G., & Vacher, G. (2024). Understanding the impact of polyunsaturated fatty acids on age-related macular degeneration: a review. *International Journal of Molecular Sciences*, *25*(7), 4099.
13. Thomsen, A. K., Steffensen, M. A., Villarruel Hinnerskov, J. M., Nielsen, A. T., Vorum, H., Honoré, B., ... & Sørensen, T. L. (2024). Complement proteins and complement regulatory proteins are associated with agerelated macular degeneration stage and treatment response. *Journal of Neuroinflammation*, *21*(1), 284.
14. Matsumoto, H., Hoshino, J., Nakamura, K., & Akiyama, H. (2024). One-year results of treat-and-extend regimen with intravitreal faricimab for treatment-naïve neovascular age-related macular degeneration. *Japanese Journal of Ophthalmology*, *68*(2), 83-90.
15. Liu, S., Liu, Y., Wu, X., Wang, H., Jin, Z., Wang, P., ... & Zhou, W. (2025). Efficacy and prognostic factors of anti-VEGF treatment for neovascular age-related macular degeneration: An OCTA imagingbased deep learning analysis. *Photodiagnosis and Photodynamic Therapy*, 104701.
16. Wada, I., Oshima, Y., Fukuda, Y., Shiose, S., Kano, K., Ishikawa, K., ... & Sonoda, K. H. (2025). Five-year outcome of aflibercept administration with “treat and extend” for neovascular age-related macular degeneration. *Clinical Ophthalmology*, 835-845.

Pharmacology journal volume-13-issue 2
Journal link: https://pharmacologyjournal.org/
Submission 18 Jan 2025
Acceptance 9 Feb 2025
Publication 05 March 2025

17. Borchert, G. A., Kiire, C. A., Stone, N. M., Akil, H., Gkika, T., Fischer, M. D., ... & De Silva, S. R. (2024). Real-world six-month outcomes in patients switched to faricimab following partial response to anti-VEGF therapy for neovascular age-related macular degeneration and diabetic macular oedema. *Eye*, *38*(18), 35693577.

18. Cheng, S., Zhang, S., Huang, M., Liu, Y., Zou, X., Chen, X., & Zhang, Z. (2024). Treatment of neovascular age-related macular degeneration with anti-vascular endothelial growth factor drugs: progress from mechanisms to clinical applications. *Frontiers in Medicine*, *11*, 1411278.

Pharmacology journal volume-13-issue 2
Journal link: https://pharmacologyjournal.org/
Submission 18 Jan 2025
Acceptance 9 Feb 2025
Publication 05 March 2025